A paper, made visible
Semaglutide and Exercise Function in Obesity-Related HFpEF: Insights From the STEP-HFpEF Program.
- Available sources do not yet support a numeric visual.
What the available source describes
Study context is available. A quantitative result is not established here.
Study context 1 · source-backed descriptions
No supported numerical result is available for this comparison. No supported numeric visual is available.
Who or what was studied
patients with obesity-related HFpEF
What was examined
semaglutide
placebo
Outcome named in the source
exercise function
Inspect the source trail for this comparison
- Paper abstract ↗ · Abstractabstract · Matched to source text; not expert scientific review
Semaglutide-mediated improvements in HF-related symptoms, physical limitations, and exercise function were consistent across the spectrum of baseline 6MWD, observed as early as 20 weeks after the initiation of treatment, preceding maximal weight loss.
- Paper abstract ↗ · Abstractabstract · Matched to source text; not expert scientific review
RESULTS: The authors randomized 1,145 patients to semaglutide or placebo.
- Paper abstract ↗ · Abstractabstract · Matched to source text; not expert scientific review
Treatment with semaglutide increased KCCQ-CSS and reduced body weight, reduced C-reactive protein, improved the hierarchical composite (death, heart failure events, change in KCCQ-CSS and 6MWD), and reduced N-terminal pro-B-type natriuretic peptide across the spectrum of baseline 6MWD (all P CONCLUSIONS: In patients with obesity-related HFpEF, impaired 6MWD is most strongly associated with excess adiposity, congestion, and inflammation.
Study context 2 · source-backed descriptions
No supported numerical result is available for this comparison. No supported numeric visual is available.
Who or what was studied
patients with obesity-related HFpEF
What was examined
semaglutide
placebo
Outcome named in the source
Inspect the source trail for this comparison
- Paper abstract ↗ · Abstractabstract · Matched to source text; not expert scientific review
Treatment with semaglutide increased 6MWD compared with placebo, an effect apparent at 20 weeks (treatment difference 14.6 m [95% CI: 8.6-20.7 m]; P < 0.0001) that was maintained at 52 weeks (treatment difference 17.1 m [95% CI: 9.2-25.0 m]; P < 0.0001).
- Paper abstract ↗ · Abstractabstract · Matched to source text; not expert scientific review
Treatment with semaglutide increased KCCQ-CSS and reduced body weight, reduced C-reactive protein, improved the hierarchical composite (death, heart failure events, change in KCCQ-CSS and 6MWD), and reduced N-terminal pro-B-type natriuretic peptide across the spectrum of baseline 6MWD (all P CONCLUSIONS: In patients with obesity-related HFpEF, impaired 6MWD is most strongly associated with excess adiposity, congestion, and inflammation.
Study context 3 · source-backed descriptions
No supported numerical result is available for this comparison. No supported numeric visual is available.
Who or what was studied
patients with obesity-related HFpEF
What was examined
excess adiposity, congestion, and inflammation
Outcome named in the source
Inspect the source trail for this comparison
- Paper abstract ↗ · Abstractabstract · Matched to source text; not expert scientific review
Impaired 6MWD is most strongly associated with excess adiposity, congestion, and inflammation.
- Paper abstract ↗ · Abstractabstract · Matched to source text; not expert scientific review
Treatment with semaglutide increased KCCQ-CSS and reduced body weight, reduced C-reactive protein, improved the hierarchical composite (death, heart failure events, change in KCCQ-CSS and 6MWD), and reduced N-terminal pro-B-type natriuretic peptide across the spectrum of baseline 6MWD (all P CONCLUSIONS: In patients with obesity-related HFpEF, impaired 6MWD is most strongly associated with excess adiposity, congestion, and inflammation.
Study context 4 · source-backed descriptions
The numerical result is withheld from this picture. The estimate and interval could not be bound to one explicit statistical expression in the source.
What was examined
semaglutide
placebo
Inspect the source trail for this comparison
- Paper abstract ↗ · Abstractabstract · Matched to source text; not expert scientific review
Treatment with semaglutide increased 6MWD compared with placebo, an effect apparent at 20 weeks (treatment difference 14.6 m [95% CI: 8.6-20.7 m]; P < 0.0001) that was maintained at 52 weeks (treatment difference 17.1 m [95% CI: 9.2-25.0 m]; P < 0.0001).
Study context 5 · source-backed descriptions
The numerical result is withheld from this picture. The estimate and interval could not be bound to one explicit statistical expression in the source.
What was examined
semaglutide
placebo
Inspect the source trail for this comparison
- Paper abstract ↗ · Abstractabstract · Matched to source text; not expert scientific review
Treatment with semaglutide increased 6MWD compared with placebo, an effect apparent at 20 weeks (treatment difference 14.6 m [95% CI: 8.6-20.7 m]; P < 0.0001) that was maintained at 52 weeks (treatment difference 17.1 m [95% CI: 9.2-25.0 m]; P < 0.0001).